SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ImmunityBio converts from Immunomedics
IBRX 2.400+1.7%Oct 31 9:30 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: jargonweary who wrote (1101)7/16/2025 8:10:47 PM
From: waitwatchwander1 Recommendation

Recommended By
bobbseytwins2001

   of 1221
 
Anktiva is an expensive life extending treatment. There is only a certain class of people who can afford and be helped by it.

Getting the word out in whatever way one can is required for this drug to be successful. It is sure to be a slow and steady climb to cash flow positive and profitability or sale to a greater enabler.

PSS does understand this part of the challenge. Success to him is helping all that he can muster into the Anktiva camp. JMO
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News